methotrexate (1102-39) / Atlanthera - LARVOL DELTA

Design, Synthesis, and Characterization of HBP-Vectorized Methotrexate Prodrug Molecule 1102-39: Evaluation of In Vitro Cytotoxicity Activity in Cell Culture Models, Preliminary In Vivo Safety and Efficacy Results in Rodents. (PubMed, ACS Omega) - "Furthermore, various aspects of designing molecules for selective therapy in bone tissue based on bisphosphonate molecules as vectors for delivering active compounds to the bone are discussed. The 1102-39 molecule exhibits strong affinity for hydroxyapatite and a progressive release of MTX in aqueous environments, enhancing the safety and efficacy of bone-specific treatments and enabling sustained activity within bone and bone joints in the therapy of tumor and inflammation."

Journal • Preclinical • Oncology • Osteosarcoma • Sarcoma • Solid Tumor

Treatment Outcomes for up to 2 Years in Patients Aged Less Than 12 Years with Inadequately Controlled Moderate-to-Severe Atopic Dermatitis: Real-World Data From PEDISTAD (ACD-ASM 2023) - P=N/A | N= 161 | NCT03849716 | Sponsor: Sanofi | "144 patients received dupilumab (mean treatment observation period: 9.4 months), 114 received methotrexate (13.7 months), 121 received cyclosporine (11.8 months). The most common baseline type 2 inflammatory comorbidities were food allergies (dupilumab: 54.2%, methotrexate: 43.2%) and allergic rhinitis (cyclosporine: 42.5%)....AE rates were 18.1% dupilumab, 29.8% methotrexate, and 31.4% cyclosporine whilst accumulated 2-year discontinuation rates were 8.3% for dupilumab, 28.9% for methotrexate and 43.0% for cyclosporine."

Psoriasis vs. Eczema: Differences, Images, Treatment - "Eczema and psoriasis, while two distinct conditions, have something key in common. Both these diseases, says Dr. Amy Paller...Dr. Paller explained that eczema is usually 'characterized by poorly demarcated red, dry areas with fine scale,' while psoriasis appears as 'red, well-circumscribed lesions (called plaques) with heaped-up, white scaling.'"

Media quote • Psoriasis

Daniel P. Petrylak, MD, Talks About Importance of Mentorships in Genitourinary Oncology (Cancer Network) - "At the 15th Annual Interdisciplinary Prostate Cancer Congress and Other Genitourinary Malignancies, Daniel P. Petrylak, MD, reflects upon mentorship during his training to become an oncologist."

Video